Novo Nordisk A/S: Ryzodeg® (insulin degludec/insulin aspart) Passed the Review by the First Committee on Drugs of Pharmaceutical Affairs in Japan

BAGSVAERD, DENMARK--(Marketwire - December 03, 2012) -

Novo Nordisk today announced that Ryzodeg® (insulin degludec/insulin aspart) has passed the review by the First Committee on Drugs of Japan’s Pharmaceutical Affairs. The remaining step in the regulatory process is an approval from the Ministry of Health, Labour and Welfare.

Company announcement No 78 / 2012: http://hugin.info/2013/R/1661613/538373.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1661613]